Abcellera Biologics Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ABCL moving today?
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ABCL overview
Related filings and maps
Congress activity in ABCL
No receipt-qualified Congressional disclosure is present for ABCL in the cached public ledger.
ABCL contract awards, year to date.
Public federal awards linked to this ticker.
ABCL lobbying filings, year to date.
Registered lobbying filings matched to Abcellera Biologics Inc.